Selva Therapeutics, Inc. is an early stage pharmaceutical company focusing on the development of therapeutics for infectious diseases. Selva’s lead compound, S-001, is highly active against coronaviruses such as SARS-CoV-2 that is responsible for Covid-19. The company is located in San Diego, California.

SELVA LEAD PROGRAM

Selva Lead Program

Coronaviruses must enter host cells to replicate. Cell entry by the virus is mediated by proteases found in the host. S-001 is an inhibitor of these proteases and prevents the virus from binding to receptors needed for entry into the host cell. In addition to activity against coronaviruses, S-001 has shown activity against filoviruses such as Ebola, and the parasite T. cruzi, which is responsible for the development of Chagas disease.

FOUNDERS

Ted Daley, President & CEO

Mr. Daley was previously President and Chief Business Officer for Raptor Pharmaceuticals. He joined Raptor through its acquisition of Convivia, Inc., which he founded. He also co-founded and was Chief Operating Officer for Instill Corporation, a pioneering e-commerce company. Mr. Daley has advised and consulted for numerous technology and life science start-ups, and currently serves on the Board of Directors of Empire Biotechnologies.

Felix Frueh, PhD. Chief Science Officer

Dr. Frueh was previously CSO at Human Longevity, Inc. and Co-Founder and CEO of Intellos Health. He was an Entrepreneur-in-Residence at Third Rock Ventures and the former President of the Medco Research Institute. Dr. Frueh was the first Associate Director for Genomics at FDA and held executive positions in multiple biotechnology companies. He serves on the Boards of several biotechnology corporations and non-profit organizations. Felix is a Fellow of the American College of Clinical Pharmacology and held faculty positions at Georgetown University in Washington, DC and at the University of North Carolina.

ADVISORY BOARD

James McKerrow, MD, PhD. Scientific Advisor

Dr. McKerrow is the Dean of Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego Health Sciences. Prior to this, he served as Professor of Pathology and Director of the Center for Discovery and Innovation in Parasitic Diseases, UC San Francisco. Dr. McKerrow founded and served as chief executive officer of Demeter Pharmaceuticals, a non-profit company focusing on acquisition and screening of the largest marine natural products library in the United States. He is a member of the American Society for Cell Biology, American Society of Microbiology, American Society of Biochemistry and Molecular Biology, American Society of Tropical Medicine and Hygiene, American Society of Parasitologists and the American Society of Immunologists.

Sheba Meymandi, MD. Scientific Advisor

Dr. Sheba K. Meymandi is the director of the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, which opened in 2007 as the first U.S. clinic for the diagnosis and treatment of Chagas disease. Dr. Meymandi is a Clinical Professor of Medicine at UCLA’s David Geffen School of Medicine, the Associate Medical Director of Olive View-UCLA Medical Center and the Director of Cardiovascular Research and Invasive Cardiology at Olive View-UCLA Medical Center.

Kenneth J. Kelley, MBA. Strategic Advisor

Mr. Kelley is assisting Selva with funding and corporate development. He was a White House Presidential Executive Fellow, Advisor to the Biomedical Advanced Research and Development Authority (BARDA) and to the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) on emerging infectious disease threats. Mr. Kelley is co-founder and/or director on the Boards at Adjuvance Technologies, SeromYx Systems, Meissa Vaccines, ID Biologics, and Public Health Vaccines, LLC. He also was the Founder and CEO of PaxVax.

Thomas E. Dans, CFA Strategic Advisor

Mr. Dans is assisting Selva with funding and government relations. He is a seasoned entrepreneur who also serves as CFO of Ceretype Neuromedicine, among other duties. His career includes principal investing roles at Allen & Company Incorporated and Evercore Partners.

Contact Us